publication . Article . 2020

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease

Kang, M. S.; Aliaga, A. A.; Shin, M.; Mathotaarachchi, S.; Benedet, A. L.; Pascoal, T. A.; Therriault, J.; Chamoun, M.; Savard, M.; Devenyi, G. A.; ...
Open Access English
  • Published: 26 Jun 2020
  • Country: United Kingdom
Neurofilament light chain (NFL) measurement has been gaining strong support as a clinically useful neuronal injury biomarker for various neurodegenerative conditions. However, in Alzheimer’s disease (AD), its reflection on regional neuronal injury in the context of amyloid pathology remains unclear. This study included 83 cognitively normal (CN), 160 mild cognitive impairment (MCI), and 73 AD subjects who were further classified based on amyloid-beta (Aβ) status as positive or negative (Aβ+ vs Aβ−). In addition, 13 rats (5 wild type and 8 McGill-R-Thy1-APP transgenic (Tg)) were examined. In the clinical study, reduced precuneus/posterior cingulate cortex and hip...
Medical Subject Headings: mental disorders
free text keywords: Biomarkers, Diseases, Molecular biology, Neuroscience
Funded by
  • Funder: Canadian Institutes of Health Research (CIHR)
Pathways to Alzheimer's disease
  • Funder: European Commission (EC)
  • Project Code: 681712
  • Funding stream: H2020 | ERC | ERC-COG
NIH| Alzheimers Disease Neuroimaging Initiative
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
Download from
UCL Discovery
Article . 2020
47 references, page 1 of 4

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease; progress and problems on the road to therapeutics. Science. 2002;297:353-6.

2. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-16.

3. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60:729-36. [OpenAIRE]

4. Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-62.

5. Ottoy J, Niemantsverdriet E, Verhaeghe J, De Roeck E, Struyfs H, Somers C, et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging. Neuroimage Clin. 2019;22:101771.

6. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233: 183-98.

7. Trojanowski JQ, Walkenstein N, Lee VMY. Expression of neurofilament subunits in neurons of the central and peripheral nervous-system-an immunohistochemical study with monoclonalantibodies. J Neurosci. 1986;6:650-60. [OpenAIRE]

8. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosur Psychitary. 1998;64: 402-4.

9. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67:2013-8.

10. Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116-26. [OpenAIRE]

11. Zetterberg H, Skillback T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of cerebrospinal fluid neurofilament light concentration With Alzheimer disease progression. JAMA Neurol. 2016;73:60-7.

12. Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:56-66. [OpenAIRE]

13. Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, et al. Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology. 2018;90: e717-e23.

14. Soylu-Kucharz R, Sandelius A, Sjogren M, Blennow K, Wild EJ, Zetterberg H, et al. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice. Sci Rep. 2017;7:14114.

15. Brureau A, Blanchard-Bregeon V, Pech C, Hamon S, Chaillou P, Guillemot JC, et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol Dis. 2017;104:73-84. [OpenAIRE]

47 references, page 1 of 4
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue